Given its greater efficiency and lower costs compared to murine models, our zebrafish experimental system appears ideal for pursuing additional classes of pathway inhibitors in NF1/PTEN-mutant melanomas, as single agents and in combination, to define their clinical translational potential. This evidence concerns the gene NF1 and melanoma.